Authors
Michael Thompson, Martin Helan, Li Drake, Benjamin Roos, Christina M Pabelick, Y S Prakash
Published in
Pulmonary circulation. Volume 16. Issue 4. Pages e70450. Epub Nov 06, 2026.
Abstract
Hypoxia is a well-recognized risk factor in several pulmonary vascular diseases, including pulmonary hypertension (PH). Furthermore, hypoxia-associated inflammatory changes enhance the structural and functional changes in the pulmonary artery (PA) of PH patients. Understanding the mechanisms that link hypoxia and inflammation, particularly early in disease, is key to the development of novel therapeutic avenues for PH. Thymic stromal lymphopoietin (TSLP) is an "early" inflammatory mediator thought to be critical in diseases such as asthma, chronic obstructive pulmonary disease, and atopic dermatitis. TSLP has canonical effects on the immune system, but can also have non-canonical effects on resident lung cells, for example, airway smooth muscle. Currently, the expression and role of TSLP in the PA are unknown. We hypothesized that locally produced TSLP potentiates the effects of hypoxia in PA remodeling and contractility relevant to PH. Experiments in human PA endothelial cells (PAECs) and smooth muscle cells (PASMCs) found PAECs to be a larger source of TSLP, which targets PASMCs to enhance intracellular Ca2+ responses and contractility to vasoconstrictor agonists, as well as cell proliferation and extracellular matrix deposition, acting via a number of signaling cascades including Stat3 and PI3/Akt. Hypoxia, acting via HIF1α, enhanced PAEC production of TSLP and promoted TSLP effects on PASMCs. Interestingly, TSLP per se enhanced HIF1α. Overall, these novel data highlight a role for TSLP in hypoxia effects on the PA, and thus relevance for inflammation in PH.
PMID:
42999736
Bibliographic data and abstract were imported from PubMed on 08 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 7
- Comments 0